Clinical Trial Detail

NCT ID NCT02724020
Title MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Millennium Pharmaceuticals, Inc.
Indications

renal cell carcinoma

Therapies

MLN1117 + Sapanisertib

Sapanisertib

Everolimus

Age Groups: adult senior

No variant requirements are available.